939 related articles for article (PubMed ID: 21764753)
1. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding.
Scheid JF; Mouquet H; Ueberheide B; Diskin R; Klein F; Oliveira TY; Pietzsch J; Fenyo D; Abadir A; Velinzon K; Hurley A; Myung S; Boulad F; Poignard P; Burton DR; Pereyra F; Ho DD; Walker BD; Seaman MS; Bjorkman PJ; Chait BT; Nussenzweig MC
Science; 2011 Sep; 333(6049):1633-7. PubMed ID: 21764753
[TBL] [Abstract][Full Text] [Related]
2. Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing.
Wu X; Zhou T; Zhu J; Zhang B; Georgiev I; Wang C; Chen X; Longo NS; Louder M; McKee K; O'Dell S; Perfetto S; Schmidt SD; Shi W; Wu L; Yang Y; Yang ZY; Yang Z; Zhang Z; Bonsignori M; Crump JA; Kapiga SH; Sam NE; Haynes BF; Simek M; Burton DR; Koff WC; Doria-Rose NA; Connors M; ; Mullikin JC; Nabel GJ; Roederer M; Shapiro L; Kwong PD; Mascola JR
Science; 2011 Sep; 333(6049):1593-602. PubMed ID: 21835983
[TBL] [Abstract][Full Text] [Related]
3. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01.
Zhou T; Georgiev I; Wu X; Yang ZY; Dai K; Finzi A; Kwon YD; Scheid JF; Shi W; Xu L; Yang Y; Zhu J; Nussenzweig MC; Sodroski J; Shapiro L; Nabel GJ; Mascola JR; Kwong PD
Science; 2010 Aug; 329(5993):811-7. PubMed ID: 20616231
[TBL] [Abstract][Full Text] [Related]
4. Increasing the potency and breadth of an HIV antibody by using structure-based rational design.
Diskin R; Scheid JF; Marcovecchio PM; West AP; Klein F; Gao H; Gnanapragasam PN; Abadir A; Seaman MS; Nussenzweig MC; Bjorkman PJ
Science; 2011 Dec; 334(6060):1289-93. PubMed ID: 22033520
[TBL] [Abstract][Full Text] [Related]
5. AIDS/HIV. Converging on an HIV vaccine.
Korber B; Gnanakaran S
Science; 2011 Sep; 333(6049):1589-90. PubMed ID: 21921189
[No Abstract] [Full Text] [Related]
6. Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120.
Chen L; Kwon YD; Zhou T; Wu X; O'Dell S; Cavacini L; Hessell AJ; Pancera M; Tang M; Xu L; Yang ZY; Zhang MY; Arthos J; Burton DR; Dimitrov DS; Nabel GJ; Posner MR; Sodroski J; Wyatt R; Mascola JR; Kwong PD
Science; 2009 Nov; 326(5956):1123-7. PubMed ID: 19965434
[TBL] [Abstract][Full Text] [Related]
7. Isolation and characterization of a novel neutralizing antibody targeting the CD4-binding site of HIV-1 gp120.
Qiao Y; Man L; Qiu Z; Yang L; Sun Y; He Y
Antiviral Res; 2016 Aug; 132():252-61. PubMed ID: 27387828
[TBL] [Abstract][Full Text] [Related]
8. Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120.
Kong L; Lee JH; Doores KJ; Murin CD; Julien JP; McBride R; Liu Y; Marozsan A; Cupo A; Klasse PJ; Hoffenberg S; Caulfield M; King CR; Hua Y; Le KM; Khayat R; Deller MC; Clayton T; Tien H; Feizi T; Sanders RW; Paulson JC; Moore JP; Stanfield RL; Burton DR; Ward AB; Wilson IA
Nat Struct Mol Biol; 2013 Jul; 20(7):796-803. PubMed ID: 23708606
[TBL] [Abstract][Full Text] [Related]
9. Structural basis for HIV-1 gp120 recognition by a germ-line version of a broadly neutralizing antibody.
Scharf L; West AP; Gao H; Lee T; Scheid JF; Nussenzweig MC; Bjorkman PJ; Diskin R
Proc Natl Acad Sci U S A; 2013 Apr; 110(15):6049-54. PubMed ID: 23524883
[TBL] [Abstract][Full Text] [Related]
10. A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield.
Pejchal R; Doores KJ; Walker LM; Khayat R; Huang PS; Wang SK; Stanfield RL; Julien JP; Ramos A; Crispin M; Depetris R; Katpally U; Marozsan A; Cupo A; Maloveste S; Liu Y; McBride R; Ito Y; Sanders RW; Ogohara C; Paulson JC; Feizi T; Scanlan CN; Wong CH; Moore JP; Olson WC; Ward AB; Poignard P; Schief WR; Burton DR; Wilson IA
Science; 2011 Nov; 334(6059):1097-103. PubMed ID: 21998254
[TBL] [Abstract][Full Text] [Related]
11. N332-Directed broadly neutralizing antibodies use diverse modes of HIV-1 recognition: inferences from heavy-light chain complementation of function.
Pancera M; Yang Y; Louder MK; Gorman J; Lu G; McLellan JS; Stuckey J; Zhu J; Burton DR; Koff WC; Mascola JR; Kwong PD
PLoS One; 2013; 8(2):e55701. PubMed ID: 23431362
[TBL] [Abstract][Full Text] [Related]
12. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus.
Liao HX; Lynch R; Zhou T; Gao F; Alam SM; Boyd SD; Fire AZ; Roskin KM; Schramm CA; Zhang Z; Zhu J; Shapiro L; ; Mullikin JC; Gnanakaran S; Hraber P; Wiehe K; Kelsoe G; Yang G; Xia SM; Montefiori DC; Parks R; Lloyd KE; Scearce RM; Soderberg KA; Cohen M; Kamanga G; Louder MK; Tran LM; Chen Y; Cai F; Chen S; Moquin S; Du X; Joyce MG; Srivatsan S; Zhang B; Zheng A; Shaw GM; Hahn BH; Kepler TB; Korber BT; Kwong PD; Mascola JR; Haynes BF
Nature; 2013 Apr; 496(7446):469-76. PubMed ID: 23552890
[TBL] [Abstract][Full Text] [Related]
13. Structural mimicry of CD4 by a cross-reactive HIV-1 neutralizing antibody with CDR-H2 and H3 containing unique motifs.
Prabakaran P; Gan J; Wu YQ; Zhang MY; Dimitrov DS; Ji X
J Mol Biol; 2006 Mar; 357(1):82-99. PubMed ID: 16426633
[TBL] [Abstract][Full Text] [Related]
14. Structural Features of Broadly Neutralizing Antibodies and Rational Design of Vaccine.
Zhou T; Xu K
Adv Exp Med Biol; 2018; 1075():73-95. PubMed ID: 30030790
[TBL] [Abstract][Full Text] [Related]
15. Selection pressure on HIV-1 envelope by broadly neutralizing antibodies to the conserved CD4-binding site.
Wu X; Wang C; O'Dell S; Li Y; Keele BF; Yang Z; Imamichi H; Doria-Rose N; Hoxie JA; Connors M; Shaw GM; Wyatt RT; Mascola JR
J Virol; 2012 May; 86(10):5844-56. PubMed ID: 22419808
[TBL] [Abstract][Full Text] [Related]
16. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1.
Wu X; Yang ZY; Li Y; Hogerkorp CM; Schief WR; Seaman MS; Zhou T; Schmidt SD; Wu L; Xu L; Longo NS; McKee K; O'Dell S; Louder MK; Wycuff DL; Feng Y; Nason M; Doria-Rose N; Connors M; Kwong PD; Roederer M; Wyatt RT; Nabel GJ; Mascola JR
Science; 2010 Aug; 329(5993):856-61. PubMed ID: 20616233
[TBL] [Abstract][Full Text] [Related]
17. Structure of the Fab fragment of F105, a broadly reactive anti-human immunodeficiency virus (HIV) antibody that recognizes the CD4 binding site of HIV type 1 gp120.
Wilkinson RA; Piscitelli C; Teintze M; Cavacini LA; Posner MR; Lawrence CM
J Virol; 2005 Oct; 79(20):13060-9. PubMed ID: 16189008
[TBL] [Abstract][Full Text] [Related]
18. Computation-guided backbone grafting of a discontinuous motif onto a protein scaffold.
Azoitei ML; Correia BE; Ban YE; Carrico C; Kalyuzhniy O; Chen L; Schroeter A; Huang PS; McLellan JS; Kwong PD; Baker D; Strong RK; Schief WR
Science; 2011 Oct; 334(6054):373-6. PubMed ID: 22021856
[TBL] [Abstract][Full Text] [Related]
19. Bacterially expressed HIV-1 gp120 outer-domain fragment immunogens with improved stability and affinity for CD4-binding site neutralizing antibodies.
Rathore U; Purwar M; Vignesh VS; Das R; Kumar AA; Bhattacharyya S; Arendt H; DeStefano J; Wilson A; Parks C; La Branche CC; Montefiori DC; Varadarajan R
J Biol Chem; 2018 Sep; 293(39):15002-15020. PubMed ID: 30093409
[TBL] [Abstract][Full Text] [Related]
20. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1.
Roben P; Moore JP; Thali M; Sodroski J; Barbas CF; Burton DR
J Virol; 1994 Aug; 68(8):4821-8. PubMed ID: 7518527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
